Fig. 1 · Structure

Documents & Downloads

TMPA

Cat. No. A12407 CAS 1258275-73-8

Nur77 LBD Antagonist

TMPA is a novel small molecule that binds to orphan Nuclear Receptor Nur77 with high affinity (Kd = 1.45 ± 0.35 μM), and interferes with the Nur77-LKB1 interaction.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

TMPA Research Summary

This section summarizes 2 in vitro studies of TMPA from 1 published reference. In vitro models include HepG2 cells.

TMPA In Vitro Studies

TMPA significantly ameliorated lipid accumulation in HepG2 cells exposed to FFAs compared with DMSO + FFAs, as assessed by Oil red O staining. In primary hepatocytes exposed to FFAs, TMPA reduced lipid accumulation and fat vacuoles compared with DMSO + FFAs, as assessed by Oil red O stain quantification. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Reduced Lipid Accumulation in HepG2 Cells

Cell-based study · HepG2 cells [1]

In HepG2 cells exposed to FFAs, TMPA significantly ameliorated lipid accumulation compared with DMSO + FFAs, as assessed by Oil red O staining.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Oil red O stainingReported result TMPA (10µm), incubated for 6h before exposure to FFAs for 24h: TMPA significantly ameliorated lipid accumulation.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10µm
Exposure duration
incubated for 6h before exposure to FFAs for 24h
Method
added the solution to HepG2 cells and primary hepatocytes
Vehicle
dimethyl sulfoxide
Co-treatment
Other interventions in this design: FFAs mixture (OA:PA = 2:1) 0.25mM. Compound effect isolated by the comparison: DMSO + FFAs.
Methods and source locations

Compound reported in the paper: TMPA

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Reagents (S7); Methods > Induction of Fat-Overload in HepG2 Cells and Primary Hepatocytes (S16); Methods > Hematoxylin-Eosin Staining and Oil Red O Staining (S25, S26); Results > TMPA Reduced Lipid Accumulation Following FFAs Stimulation in HepG2 Cells and Primary Hepatocytes (S81); Figure 3 legend (S120, S122, S123, S124, S125)

Oil red O staining: Oil red O staining; comparator: DMSO + FFAs — Results > TMPA Reduced Lipid Accumulation Following FFAs Stimulation in HepG2 Cells and Primary Hepatocytes (S81); Figure 3 legend (S120, S123, S125)

Reduced Lipid Accumulation and Fat Vacuoles in Primary Hepatocytes

Cell-based study · primary hepatocytes [1]

In primary hepatocytes exposed to FFAs, TMPA reduced lipid accumulation and fat vacuoles compared with DMSO + FFAs, as assessed by Oil red O stain quantification.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Oil red O stain quantificationReported result TMPA (10µm), incubated for 6h before exposure to FFAs for 24h: Lipid accumulation and fat vacuoles were both reduced by TMPA.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10µm
Exposure duration
incubated for 6h before exposure to FFAs for 24h
Method
added the solution to HepG2 cells and primary hepatocytes
Vehicle
dimethyl sulfoxide
Co-treatment
Other interventions in this design: FFAs mixture (OA:PA = 2:1) 0.25mM. Compound effect isolated by the comparison: DMSO + FFAs.
Methods and source locations

Compound reported in the paper: TMPA

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Reagents (S7); Methods > Induction of Fat-Overload in HepG2 Cells and Primary Hepatocytes (S16); Methods > Hematoxylin-Eosin Staining and Oil Red O Staining (S25, S26); Results > TMPA Reduced Lipid Accumulation Following FFAs Stimulation in HepG2 Cells and Primary Hepatocytes (S81, S82); Figure 3 legend (S123, S124, S126, S127)

Oil red O stain quantification: Oil red O stain quantification; comparator: DMSO + FFAs — Results > TMPA Reduced Lipid Accumulation Following FFAs Stimulation in HepG2 Cells and Primary Hepatocytes (S81, S82); Figure 3 legend (S123, S126, S127)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 1258275-73-8
Applications Nur77 LBD Antagonist
Formula C21H32O6
Molecular Weight 380.48
SMILES
CCCCCCCC(=O)C1=CC(=C(C(=C1CC(=O)OCC)OC)OC)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

TMPA Research References

  1. [1] Wang X, Li G, Guo C, et al. Ethyl 2-[2,3,4-Trimethoxy-6-(1-Octanoyl)Phenyl] Acetate (TMPA) Ameliorates Lipid Accumulation by Disturbing the Combination of LKB1 with Nur77 and Activating the AMPK Pathway in HepG2 Cells and Mice Primary Hepatocytes. Diabetes Metab Syndr Obes (2021). PMID: 34629883 DOI: 10.2147/DMSO.S321246 Source material

Added to your cart

View Cart Checkout
Loading...